PT-141 (Bremelanotide) Compassionate Use and Expanded Access

What Is PT-141 (Bremelanotide) and Why Does Access Matter?

Bremelanotide targets the central nervous system rather than the peripheral vasculature. It acts on melanocortin receptors (MC3R and MC4R) in the hypothalamus to increase sexual desire, which distinguishes it pharmacologically from PDE5 inhibitors like sildenafil. The FDA approved it in August 2019 under NDA 210557 for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.

The HSDD Burden

HSDD affects an estimated 8 to 10 percent of premenopausal women in the United States, representing roughly 5.5 to 8 million people who meet diagnostic criteria for distressing low sexual desire. A 2018 analysis published in the Journal of Sexual Medicine (PMID 29174139) found that women with HSDD report significantly lower health-related quality of life scores compared to controls, with particular deficits in emotional well-being and personal relationships.

Despite this prevalence, treatment options have been limited. Flibanserin (Addyi) was approved in 2015 but carries a REMS requirement and alcohol interaction warning. Bremelanotide arrived as the second approved pharmacological option, but its cash price puts it out of reach for a substantial portion of patients without strong insurance coverage.

Why Access Pathways Are Complicated

Because bremelanotide is already FDA-approved, the traditional "compassionate use" framework does not apply in the way it applies to investigational new drugs. The FDA's expanded access program exists specifically for patients seeking unapproved therapies or approved therapies in unapproved populations when no comparable alternative is available. FDA Expanded Access guidance explains that once a drug holds full approval for a given indication, the primary access barrier becomes cost and coverage rather than regulatory status.

This practical distinction matters because many patients searching for "PT-141 compassionate use" are actually searching for affordable access, not a regulatory filing pathway.

Formal Expanded Access: When It Applies to Bremelanotide

Expanded access for an approved drug like bremelanotide is technically available only in narrow circumstances. The FDA's Code of Federal Regulations, 21 CFR Part 312, Subpart I permits access when the patient has a serious or life-threatening condition, no comparable alternative therapy exists, and the potential benefit justifies the risk.

Off-Label Populations Who Might Qualify

Bremelanotide is approved only for premenopausal women. Several populations fall outside this label:

• Postmenopausal women with HSDD not controlled by hormone therapy
• Men with hypoactive sexual desire or certain sexual dysfunction presentations refractory to PDE5 inhibitors
• Transgender and nonbinary patients whose hormonal milieu may not match the trial population

For postmenopausal women specifically, the RECONNECT trials that supported FDA approval enrolled only premenopausal subjects. A small but growing body of post-marketing case series suggests potential benefit in peri- and postmenopausal women, but no randomized controlled trial has confirmed this in a large sample. A physician treating a postmenopausal woman with refractory HSDD who has failed hormone therapy, flibanserin, and non-pharmacological interventions might consider filing an individual patient expanded access request with the FDA.

How to File an Individual Patient Expanded Access Request

The process involves three steps. First, the prescribing physician submits FDA Form 3926 (Individual Patient Expanded Access IND application). Second, Palatin Technologies or its commercial partner AMAG Pharmaceuticals (now acquired by Covis Pharma) must agree to provide the drug. Third, the institutional review board or a licensed physician acting in an emergency capacity must concur. The FDA typically responds to emergency requests within 24 hours and to non-emergency requests within 30 days, per FDA guidance on individual patient access.

Given the approved status of bremelanotide, manufacturer cooperation for a formal expanded access IND is unlikely for cost-related requests. Palatin Technologies is a small-cap biopharmaceutical company and does not maintain a large compassionate use infrastructure comparable to oncology manufacturers. Patients seeking cost relief should use the pathways described below.

The Vyleesi Savings Program: The Most Direct Cost-Reduction Tool

For commercially insured patients, the Vyleesi Savings Card remains the most immediate and impactful access tool. According to program terms as of early 2026, eligible patients with commercial insurance may pay as little as $99 per auto-injector unit after the card is applied. The card is not valid for patients enrolled in Medicare, Medicaid, or any other federal or state government insurance program.

Eligibility and Enrollment

Enrollment is managed through the Vyleesi website and requires:

1. A valid prescription from a licensed prescriber
2. Commercial insurance (government-pay patients are excluded)
3. US residency and age 18 or older

The card typically covers a portion of co-pay up to a defined annual maximum, which has historically been set at $3,600 per calendar year. Terms change annually, so patients should confirm current limits directly with the manufacturer. Program details are subject to change and are not guaranteed year over year.

For Uninsured Patients

Uninsured patients face the full retail price of approximately $978 per auto-injector without any manufacturer program. GoodRx and similar discount platforms may reduce this price modestly at select pharmacies, but even with GoodRx the cash price for Vyleesi typically remains above $700. This gap drives many uninsured patients toward compounding pharmacies.

Compounding Pharmacies: Access Outside the Brand

Compounding pharmacies operating under Section 503A of the Federal Food, Drug, and Cosmetic Act can legally prepare bremelanotide for individual patients when a prescriber determines that the commercially available product does not meet the patient's specific clinical needs. This is the most common real-world access pathway for patients who cannot afford Vyleesi or who are outside the approved label.

Pricing at Compounding Pharmacies

Compounded bremelanotide peptide injections are widely available through telehealth-affiliated compounding pharmacies at prices ranging from approximately $60 to $200 per vial, depending on concentration, volume, and dispensing pharmacy. This represents an 80 to 90 percent cost reduction relative to brand Vyleesi.

What the FDA Says About Compounded Bremelanotide

The FDA's position on compounded versions of approved drugs is nuanced. Under 21 CFR 503A, compounding is permitted when it is performed by a licensed pharmacist or physician, is based on a valid prescription for an individual patient, and the compounded product is not essentially a copy of a commercially available product. The "essentially a copy" restriction has been interpreted inconsistently across jurisdictions. The FDA has not placed bremelanotide on its list of drugs that may not be compounded (the "Demonstrably Difficult to Compound" list), so compounding remains legal as of 2026.

Patients using compounded bremelanotide should confirm that the pharmacy holds current PCAB (Pharmacy Compounding Accreditation Board) accreditation or operates under USP <797> standards for sterile preparations, given that bremelanotide is administered subcutaneously.

HSA and FSA Eligibility for PT-141

Yes. Bremelanotide purchased with a valid prescription qualifies as an eligible medical expense under IRS Publication 502, which governs Health Savings Account (HSA) and Flexible Spending Account (FSA) reimbursements. IRS Publication 502 defines eligible expenses as those primarily for the diagnosis, cure, mitigation, treatment, or prevention of disease. A prescription-only medication for a recognized medical condition (HSDD is listed in DSM-5 as "female sexual interest/arousal disorder" or can be coded under ICD-10 F52.0) qualifies.

Practical Steps for HSA/FSA Reimbursement

Patients paying out-of-pocket for bremelanotide (whether brand or compounded) can submit the pharmacy receipt and a copy of the prescription to their HSA or FSA administrator. Most administrators accept electronic submissions. Over-the-counter purchases without a prescription do not qualify, but bremelanotide is a Schedule-unscheduled prescription drug and always requires a prescription, so the eligibility condition is always met when the product is legally dispensed.

Using an HSA/FSA to pay for compounded bremelanotide at $120 per vial, a patient in the 22 percent federal tax bracket effectively pays approximately $93.60 after tax savings. That reduction compounds (no pun intended) with any applicable state income tax exclusion.

Telehealth Prescribing and Cost Transparency

Most patients in 2026 access bremelanotide through telehealth platforms rather than traditional in-person endocrinology or gynecology clinics. Telehealth prescribers can be more attuned to cost pathways because their patient populations frequently include cash-pay individuals. A HealthRX physician reviewing a patient's HSDD presentation will typically evaluate:

1. Insurance status and formulary tier for Vyleesi
2. Eligibility for the Vyleesi Savings Card
3. Clinical appropriateness of a compounded formulation versus brand
4. HSA/FSA account availability
5. Patient preference for injection frequency and dosing flexibility

This structured cost-access review prevents the common scenario in which a patient receives a prescription for brand Vyleesi, discovers the $978 price at the pharmacy counter, and abandons the prescription entirely.

What Prescribers Should Document

For patients receiving compounded bremelanotide, the prescribing record should document the clinical rationale for compounding. Acceptable rationales include commercial product unavailability at the patient's pharmacy, financial inaccessibility of the brand product, and patient-specific formulation needs (such as a different concentration to allow dose titration). This documentation supports legal compounding under 503A and may also support HSA/FSA reimbursement if the administrator questions the prescription.

Clinical Efficacy Data: What Patients and Prescribers Should Know

Access pathways matter only if the drug works. The key phase 3 trials for bremelanotide, RECONNECT I and RECONNECT II, were published in the Journal of the American Medical Association (JAMA) in 2019. Combined, the trials enrolled 1,267 premenopausal women with HSDD. Participants receiving bremelanotide 1.75 mg subcutaneous as needed showed a statistically significant increase in the number of satisfying sexual events (SSEs) compared to placebo at 24 weeks, with the treatment difference reaching 0.7 additional SSEs per month (P<0.001). JAMA 2019;322(5):433-445

Bremelanotide also produced a statistically significant reduction in distress related to low sexual desire, measured by the Female Sexual Distress Scale-Desire (FSDS-DAO) item 13. The FDA noted in its approval summary that the clinical meaningfulness of the SSE improvement was modest but statistically consistent across both trials.

Safety Profile at Approved Doses

The most common adverse events in the RECONNECT trials were:

• Nausea: 40 percent of bremelanotide patients versus 1 percent placebo
• Flushing: 20 percent versus 2 percent placebo
• Injection site reactions: 13 percent versus 3 percent placebo
• Transient blood pressure increases: mean systolic increase of 1.8 mmHg at one hour post-dose; resolved within 12 hours in most patients

The FDA label includes a warning against use in patients with cardiovascular disease or uncontrolled hypertension. FDA prescribing information for Vyleesi specifies that bremelanotide is not recommended in patients with known cardiovascular disease because of the transient blood pressure effect.

Dose and Administration

The approved dose is 1.75 mg injected subcutaneously in the abdomen or thigh approximately 45 minutes before anticipated sexual activity. Patients should not use more than one dose within 24 hours and should limit use to approximately eight doses per month based on safety data. The auto-injector pen used in Vyleesi delivers the full dose in a single activation.

Compounded formulations often come as multi-dose vials at concentrations of 10 mg/mL (1 mL = 10 mg) or 5 mg/mL, allowing dose adjustment with an insulin syringe. This titration flexibility is one reason some clinicians prefer the compounded form for patients who experience significant nausea at the 1.75 mg standard dose. Starting at 1.0 mg and titrating up may reduce nausea incidence, though no randomized trial has confirmed this clinically.

Off-Label Uses Being Investigated

Male Sexual Dysfunction

Bremelanotide originated as a peptide analog of alpha-melanocyte stimulating hormone (alpha-MSH) and was initially investigated in men with erectile dysfunction before the HSDD indication was pursued. Early phase 2 data showed spontaneous erections in men, which led to the original interest in the compound. A review published in Sexual Medicine Reviews (PMID 26752136) summarized the melanocortin system's role in both male and female sexual response, noting that MC4R agonism appears to drive pro-erectile effects centrally.

Men with psychogenic or mixed-etiology erectile dysfunction who have failed PDE5 inhibitors may present to physicians seeking access to PT-141. This population has no approved indication and would require off-label prescribing. Prescribers considering this use should document the failed PDE5 inhibitor trials, the absence of an approved alternative for psychogenic ED, and the patient's informed consent regarding off-label use.

Cancer Treatment-Related Sexual Dysfunction

Chemotherapy and endocrine therapy for hormone-sensitive cancers (breast, ovarian, prostate) frequently cause severe sexual dysfunction. Aromatase inhibitors, in particular, are associated with rates of HSDD exceeding 40 percent in women receiving adjuvant therapy for early-stage breast cancer. These patients are often postmenopausal (either naturally or treatment-induced) and fall outside the bremelanotide approval. An Endocrine Society Clinical Practice Guideline on female sexual dysfunction published in 2019 notes the limited pharmacological options in this population and the need for additional approved treatments.

For this group, a formal expanded access application or well-documented off-label prescription may be clinically appropriate. The physician's documentation should connect the patient's condition to the unmet need clearly, given the regulatory environment for off-label use in oncology contexts.

Insurance Coverage Field in 2026

Commercial coverage for Vyleesi remains inconsistent. A 2023 analysis by the Drug Channels Institute found that fewer than 30 percent of commercial formularies covered Vyleesi at any tier, reflecting ongoing payer skepticism about the clinical meaningfulness of the effect size in the RECONNECT trials. Plans that do cover it often place it on Tier 3 or Tier 4, resulting in co-pays of $150 to $350 per fill even before deductibles.

Medicare does not cover Vyleesi because sexual dysfunction medications are explicitly excluded from Medicare Part D coverage under 42 CFR 423.120(b)(2). Medicaid coverage varies by state; as of early 2026, fewer than 12 states include bremelanotide on their preferred drug lists.

Prior Authorization Hurdles

When Vyleesi is covered, most plans require prior authorization. Typical PA criteria include:

• Documented diagnosis of HSDD by a qualified clinician
• Documented failure or contraindication to psychotherapy or sex therapy
• Premenopausal status confirmed by FSH and estradiol levels
• Absence of a comorbid medical cause (thyroid, depression, medication side effects) that could explain the desire disorder

Gathering this documentation before submitting the PA request significantly improves approval rates. HealthRX physicians routinely assemble this clinical package during the patient visit to reduce turnaround time from prescription to approval.

Patient Assistance and 340B Programs

Palatin Technologies does not operate a formal patient assistance program (PAP) comparable to large pharmaceutical manufacturers. Patients who are uninsured and below income thresholds may request compassionate donation of drug directly from Palatin Technologies' medical affairs department, but approval is case-by-case and the volume of drug available through this channel is limited.

340B-covered entities (federally qualified health centers, Ryan White HIV/AIDS Program grantees, and similar safety-net providers) may purchase Vyleesi at the 340B ceiling price, which can reduce the acquisition cost by 25 to 50 percent. Patients receiving care at a 340B-eligible facility should ask whether their clinic dispenses through a 340B pharmacy. This pathway is underused because few safety-net clinics have historically prioritized HSDD treatment.